Systemic therapy for advanced gastric cancer: a clinical practice guideline. - Wikidata - awgldk - TriplyDB

Systemic therapy for advanced gastric cancer: a clinical practice guideline.

Systemic therapy for advanced gastric cancer: a clinical practice guideline.

http://www.wikidata.org/entity/Q37923311

about

Peripheral venous blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy.Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.Sinomenine sensitizes gastric cancer cells to 5-fluorouracil in vitro and in vivo Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models.Targeted therapies for lung cancer: clinical experience and novel agents Which is better for gastric cancer patients, perioperative or adjuvant chemotherapy: a meta-analysis.Intestinal metaplasia and the risk of gastric cancer in an immigrant asian population.Metastatic gastric cancer treatment: a little slow but worthy progress.Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong.Regenerating Family Member 4 (Reg4) Enhances 5-Fluorouracil Resistance of Gastric Cancer Through Activating MAPK/Erk/Bim Signaling Pathway.Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer.Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy.Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer.High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients.Enhanced RegIV expression predicts the intrinsic 5-fluorouracil (5-FU) resistance in advanced gastric cancer.

P2860

Q33714143-804D67BC-FDF6-43B5-9145-D5142502F69F Q34362184-6EEB0939-E724-42D8-B790-376712469131 Q35048000-2542E80F-D223-45A6-B2E1-D1F1DC9F52BA Q35998729-564DA073-DEA9-41ED-A002-E96DDF3F4EB6 Q36054970-F53B4D70-42A7-4792-8BA9-AFFD82CEDEB8 Q36103180-9B1BC8BE-6806-493A-9E1B-334E573EF285 Q37704530-21F4408D-309C-442C-A2F2-6609CF006106 Q38075499-19EE4F16-377B-420C-84DF-3A38A4F555EB Q38918414-3A12F7B1-4F64-4933-9AFE-039F55DBE44A Q40101289-E4ED6163-3EF5-490D-91D4-970209EB5065 Q45306704-EFB48283-9CAA-447D-BF5B-D6E02FD07FF0 Q47144018-EF058392-02E4-4B53-9336-B7D2339D4F67 Q50700149-29474709-13AC-48C1-89AA-78A28DA0FB6B Q53247758-EEC24EE3-294B-4AAA-8F20-02C258DE8789 Q54290367-D64596D2-F717-4FA4-BA16-D7E055214619

P2860

Systemic therapy for advanced gastric cancer: a clinical practice guideline.

http://www.wikidata.org/entity/Q37923311

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Systemic therapy for advanced gastric cancer: a clinical practice guideline.

@en

Systemic therapy for advanced gastric cancer: a clinical practice guideline.

@nl

type

label

Systemic therapy for advanced gastric cancer: a clinical practice guideline.

@en

Systemic therapy for advanced gastric cancer: a clinical practice guideline.

@nl

prefLabel

Systemic therapy for advanced gastric cancer: a clinical practice guideline.

@en

Systemic therapy for advanced gastric cancer: a clinical practice guideline.

@nl

P1433

Q37923311-0926E5E0-766B-4BCE-A20C-C8E680027389

P1476

Q37923311-E668F656-F50B-423D-865F-2997EDFE82F6

P2093

Q37923311-11A07E17-7742-4CCC-954F-5825C5E27E02

Q37923311-6FEA2C03-D210-4894-990C-903ED8B4384E

Q37923311-A02931EC-DA58-4EC3-ADD9-4F58C18664D7

P2860

Q37923311-03874870-D8E0-4CFD-8CDA-B7A32B633DAC

Q37923311-0A8DA2CF-5D03-4BA7-B9E3-062779B92A5F

Q37923311-165826BB-90CB-4907-A35B-F23775BD7CB7

Q37923311-1A1B3D3D-5EC7-4C29-A80D-A3AAFA4062A4

Q37923311-1B0FC32F-11DF-42C8-8745-324609108F54

Q37923311-28C221E4-8B05-47EE-9B88-399771AFDD7D

Q37923311-2EFCB12A-3E7B-4926-9BBA-4D2ED821E9C4

Q37923311-403B17A4-C354-47D7-8B56-73D7634ED346

Q37923311-4952206B-BB62-4AE1-B626-962618A587AD

Q37923311-4D04911C-8647-4BE6-A77D-1B0662099C16

P304

Q37923311-AFD6C7DF-0A57-4AE5-AC35-5AFA0889EFA9

P31

Q37923311-39191D95-3516-4DE7-AF2A-74A95C0E8B7E

P356

Q37923311-FD35D3B8-07C6-458E-A6C0-BBEC676C8D3D

P433

Q37923311-BA32825C-AE34-4FDD-A4E4-D1691D993851

P478

Q37923311-E8F34276-1A14-49B9-A93B-97B7FED9868D

P577

Q37923311-EE7D9F95-2D67-48BD-9041-77C3CB141E28

P5875

Q37923311-BCA9211E-9A39-4195-98AD-B7F16DDBD86A

P698

Q37923311-DFE1C134-030B-458D-95D5-86EA3BBC1975

P932

Q37923311-C30B3870-447F-4C16-A369-F950EC6AC765

P356

P1433

Current Oncology

P1476

Systemic therapy for advanced gastric cancer: a clinical practice guideline.

@en

P2093

D Jonker

http://www.w3.org/2001/XMLSchema#string

K Spithoff

http://www.w3.org/2001/XMLSchema#string

M Mackenzie

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy for advanced gastric cancer

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Cancer statistics, 2009

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.

Bimonthly 24 h infusion of high-dose 5-fluorouracil vs EAP regimen in patients with advanced gastric cancer. A randomized phase II study.

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.

P304

e202-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.V18I4.737

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51602132

http://www.w3.org/2001/XMLSchema#string

P698

21874111

http://www.w3.org/2001/XMLSchema#string

P932

3149553

http://www.w3.org/2001/XMLSchema#string